Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma.

Autor: Crombie JL; Dana-Farber Cancer Institute, Boston, MA., Nastoupil LJ; University of Texas MD Anderson Cancer Center, Houston, TX., Redd R; Dana-Farber Cancer Institute, Boston, MA., Tang K; Baylor School of Medicine, Houston, TX., Shouse G; City of Hope Cancer Center, Duarte, CA., Herrera AF; City of Hope Cancer Center, Duarte, CA., Chow VA; University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Alliance, Seattle, WA; and., Shadman M; University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Alliance, Seattle, WA; and., Castaneda Puglianini O; Virginia Commonwealth University Medical Center, Richmond, VA., Saucier A; Dana-Farber Cancer Institute, Boston, MA., Jacobson CA; Dana-Farber Cancer Institute, Boston, MA., Armand P; Dana-Farber Cancer Institute, Boston, MA., Simmons G; Virginia Commonwealth University Medical Center, Richmond, VA.
Jazyk: angličtina
Zdroj: Blood advances [Blood Adv] 2021 Sep 28; Vol. 5 (18), pp. 3563-3567.
DOI: 10.1182/bloodadvances.2021004880
Databáze: MEDLINE